Several bispecific antibodies targeting AML antigens are being investigated in ongoing early-phase trials for relapsed/refractory AML, including agents directed against CD33, CD123, CLL-1, and FLT3 [9,120]. The gene discussed is FLT3; the disease is acute myeloid leukemia.